Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Effects of biosynthetic human proinsulin on plasma lipids in type 2 diabetes mellitus (1988)
    Springer
    Journal of molecular medicine 66 (1988), S. 1171-1174 
    Details
    ISSN: 1432-1440
    Keywords: Cholesterol ; Diabetes mellitus ; HDL-Cholesterol ; Proinsulin ; Triglycerides
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Plasma cholesterol, triglycerides, HDL2-cholesterol, and HDL3-cholesterol were studied in 18 patients with Type 2 diabetes. Prior to entering the clinical trial, the study subjects were in stable control under a fixed mixture of 20% regular and 80% NPH (isophane) biosynthetic human insulin twice daily. The patients were randomized to treatment with either biosynthetic human proinsulin or biosynthetic human NPH insulin (controls) twice daily. Glucose control was kept constant in both groups throughout the study. Of the nine patients treated with proinsulin, eight exhibited a decrease of plasma triglycerides (median decrease by 0.13 mmol/l). In contrast, all nine controls showed a rise (median increase by 0.69 mmol/l) of plasma triglycerides (p〈0.001). In keeping with the fall of plasma triglycerides, HDL2-cholesterol rose in all but one proinsulin-treated patients. Both treatment modalities reduced HDL3-cholesterol with a median decrease of 0.20 mmol/l (p〈0.01) with proinsulin and 0.26 mmol/l with NPH insulin (p〈0.05). We conclude that human proinsulin is able to reduce plasma triglycerides and to increase HDL2-cholesterol in the majority of patients with Type 2 diabetes and thus appears to alter favourably risk factors for coronary heart disease.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01727664
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Evaluation of the classical methods for the diagnosis of type III hyperlipoproteinemia (1977)
    Springer
    Journal of molecular medicine 55 (1977), S. 1025-1030 
    Details
    ISSN: 1432-1440
    Keywords: Hypercholesterinämie ; Hypertriglyzeridämie ; Dyslipoproteinämie ; Ultrazentrifugation ; Lipoproteinelektrophorese ; Hypercholesterolemia ; Hypertriglyceridemia ; Dyslipoproteinemia ; Ultracentrifugation ; Lipoprotein Electrophoresis
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Summary Familial type III hyperlipoproteinemia is characterized by the presence of elevated plasma levels of very low density lipoproteins (VLDL) which contain an increased amount of cholesterol and by the presence of a significant amount of lipoproteins with an intermediate density between that of VLDL and low density lipoproteins (LDL); the intermediate density lipoproteins, designated IDL or Lp III, have a slower electrophoretic migration rate than VLDL, and are found in the ultracentrifugal top fraction as a contaminant. Classically, the diagnosis of type III is based on the demonstration of beta-migrating lipoproteins in the ultracentrifugal top fraction (density 〈1.006), thus “floating beta-lipoprotein”. More recently, it has been proposed that an elevated VLDL-cholesterol to triglyceride ratio is diagnostic of the disorder. In the present report, we have compared the two methods for their diagnostic value and have concluded that the chemical index definition is the more reliable method for the diagnosis of type III hyperlipoproteinemia.
    Notes: Zusammenfassung Die familiäre Hyperlipoproteinämie Typ III ist gekennzeichnet durch 1) einen erhöhten Plasmaspiegel von Lipoproteinen sehr niederer Dichte (Verylowdensitylipoproteins, VLDL), welche ungewöhnlich cholesterinreich sind, und 2) durch Plasmalipoproteine mit einer Dichte zwischen der von VLLL und Lipoproteinen niederer Dichte (Lowdensitylipoproteins, LDL); diese Lipoproteine mit „Zwischendichte“ (Intermediatedensitylipoproteins, IDL oder Lp III) wandern elektrophoretisch langsamer als VLDL und werden als Verunreinigung in den in der Ultrazentrifuge flotierenden VLDL (Dichte 〈1006) gefunden. Allgemein wird die Diagnose der Hyperlipoproteinämie Typ III durch den Nachweis von Lipoproteinen gestellt, welche mit VLDL flotieren, aber elektrophoretisch mit beta-Globulinen wandern (“floating beta-lipoprotein”). Neuerlich wurde ein erhöhtes Verhältnis von VLDL-Cholesterin zu Plasmatriglyzeriden höher als 0,30 als diagnostisch für die Erkrankung beschrieben. Wir haben die beiden Methoden zur Diagnosestellung verglichen und kamen zu dem Schluß, daß die chemische Indexdefinition in der Diagnosestellung der Hyperlipoproteinämie Typ III verläßlicher ist.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01489475
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    Plasma lipoprotein(a) concentration and phenotypes in diabetes mellitus (1993)
    Springer
    Diabetologia 36 (1993), S. 47-51 
    Details
    ISSN: 1432-0428
    Keywords: Diabetes mellitus ; lipoprotein(a) ; apo(a) isoforms
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Patients with Type 1 (insulin-dependent) and Type 2 (non-insulin-dependent) diabetes mellitus are at increased risk of developing atherosclerotic vascular diseases. A variety of lipoprotein abnormalities have been described as being associated with this increased risk. In this study, apo(a) isoform frequencies and lipoprotein(a) [Lp(a)] concentrations were determined in Type 1 and Type 2 diabetic patients in order to investigate a possible contribution of Lp(a) to the increased risk for atherosclerosis in diabetes. No significant differences in plasma Lp(a) concentrations were found in two ethnically different populations (Austrians from the province of Tyrol and Hungarians from Budapest) in either type of diabetes when compared to respective control groups (91 Type 1 and 112 Type 2 diabetic patients vs 202 control subjects in the Hungarian study and 44 Type 1 diabetic and 44 Type 2 diabetic vs 125 control subjects in the Austrian study). There were also no significant apo(a) isoform frequency differences between both patient groups and control subjects in the two study groups. These data, obtained from two large ethnically different populations, provide no evidence of a contribution of Lp(a) to the increased risk for atherosclerosis in diabetes.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00399092
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 4
    Electronic Resource
    Electronic Resource
    Fenofibrate improves postprandial chylomicron clearance in II B hyperlipoproteinemia (1994)
    Springer
    Journal of molecular medicine 72 (1994), S. 294-301 
    Details
    ISSN: 1432-1440
    Keywords: Fibrates ; Postprandial lipemia ; Chylomicrons ; Lipoprotein lipase ; High-density lipoproteins
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract In 11 patients with 1113 hyperlipoproteinemia we studied fasting lipids, lipoproteins, lipoprotein-modifying enzymes, and postprandial lipid metabolism after a standardized oral fat load supplemented with vitamin A before and 12 weeks after treatment with fenofibrate, a third-generation fibric acid derivative. Fasting plasma cholesterol, triglycerides, low-density lipoprotein cholesterol decreased significantly (P 〈 0.05, P 〈 0.01, P 〈 0.01), high-density lipoprotein subfraction 3 cholesterol increased significantly (P 〈 0.05), and high-density lipoprotein subfraction 2 cholesterol remained unchanged. Postprandial lipemia, i.e., the integrated postprandial triglyceride concentrations corrected for the fasting triglyceride level, and postprandial chylomicron concentrations, as assessed by biosynthetic labeling of chylomicrons with retinyl palmitate, decreased by 40.6% and 60.1% (P 〈 0.05; P 〈 0.05), respectively. The activity of lipoprotein lipase (LPL) increased by 33.6% (P 〈 0.05); the increase in LPL during fenofibrate treatment was positively correlated with the increase in high-density lipoprotein cholesterol (r = 0.84; P 〈 0.005). Hepatic lipase and cholesteryl ester transfer protein mass and activity remained unchanged. We conclude that lipid-lowering therapy with fenofibrate ameliorates fasting and, more profoundly, postprandial lipoprotein transport in hypertriglyceridemia by curbing postprandial triglyceride and chylomicron accumulation, at least in part, through an increase in LPL activity.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00180044
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...